In an effort to establish cytolytic T lymphocytes (CTLs) against colorectal carcinoma (CRC) by stimulating patients' lymphocytes with autologous tumor cells, we used peripheral blood mononuclear cells (PBMC) from a patient with minimal residual rectal carcinoma following removal of the primary lesio
Stimulation of T cells by autologous mononuclear leukocytes and epidermal cells in psoriasis
β Scribed by R. E. Schopf; A. Hoffmann; M. Jung; B. Morsches; K. Bork
- Publisher
- Springer-Verlag
- Year
- 1986
- Tongue
- English
- Weight
- 569 KB
- Volume
- 279
- Category
- Article
- ISSN
- 0340-3696
No coin nor oath required. For personal study only.
β¦ Synopsis
Based on reports suggesting aberrant cellmediated immunity and altered infiltration of immunocompetent cells into the skin in psoriasis, we studied the stimulation of T cells by autologous non-T mononuclear ieukocytes (autologous mixed lymphocyte reaction, AMLR) and by epidermal cells isolated from iesional and clinically uninvolved skin in psoriasis (autologous mixed epidermal cell lymphocyte reaction, AMECLR)
. Age-and sex-matched individuals served as controls. We found that the AMLR in psoriasis (n = 11) was similar to that in healthy controls (n = 16); furthermore, cell proliferation was alike in the presence of either 5% AB-serum or antologous serum. By contrast, while the AMECLR in healthy controls (n = 9) resembled that in psoriatics employing epidermal cells from univolved skin, epidermal cells from lesional sites (n = 10) induced a significantly higher proliferation of autologous T cells in the AMECLR (P < 0.01). We conclude that the in vitro stimulation of T cells by non-T mononuclear leukocytes is normal in psoriasis and is not regulated by autologous serum. Lesional psoriatic epidermal cells, however, are more active in stimulating autologons T cell proliferation than cells from univolved psoriatic or normal epidermis.
π SIMILAR VOLUMES
## ABSTRACT Evidence for a key role of T cells in the pathogenesis of psoriasis has come from both experimental and clinical data. Initially, generalized immunosuppressants, intended for use in transplant settings, were found to improve clinical signs and symptoms of psoriasis. Their efficacy attra